Adrenomed closes €24 million financing led by Wellington Partners and HBM26. November 2018|In Portfolio News|By eazee-designstudioAdrenomed AG, the vascular integrity company, today announced the closing of a €24 million series D financing round. The new funds will be invested in the clinical development program of lead product candidate Adrecizumab. Adrecizunab is currently tested in a phase II clinical trial in patients with early septic shock and elevated plasma Adrenomedullin concentrations (bio-ADM). PrevNext
